REMARKS

Claims 11-75 are canceled as drawn to non-elected inventions. These claims are canceled without prejudice or disclaimer. Applicant reserves the right to pursue the subject matter of the canceled claims in this, or a related application.

Response to Restriction Requirement:

The Examiner has issued a restriction requirement for election of one of the following inventions:

I. Claims 1-10, drawn to a polynucleotide encoding the granzyme B amino acid sequence set forth in SEQ ID NO:3 - including SEQ IDs NOs:1 and 2 - to vectors comprising the polynucleotide, and to a first method of use thereof in making the polypeptide in a host cell transformed or transfected with the polynucleotide, classified, *inter alia*, in class 435, subclass 69.1.

II. Claims 13, 14, and 42, drawn to an isolated granzyme B having the amino acid sequence set forth in SEQ ID NO:3, and to a first of use of the protease in an assay method for identifying modulators of its activity, classified in class 435, subclass 226.

III. Claims 15-17, drawn to a method of use of an antisense compound to inhibit expression of a granzyme B in tissues or cells comprising contacting the tissues or cells with the compound, classified in class 536, subclass 24.5.

IV. Claims 18, 19, and 22-24 draw in part to, and claim 20 drawn entirely to, a method of screening for neurological disorders by assessing the cellular expression of a granzyme B-encoding mRNA transcript, classified in class 435, subclass 6.

V. Claims 18, 19, and 22-24 draw in part to, and claim 21 drawn entirely to, a method of screening for neurological disorders by assessing the expression in cells of a granzyme B by detecting the protease, classified in class 435, subclass 7.4.

VI. Claims 25 and 26, drawn to a method of screening for autoimmune diseases by assessing granzyme B expression with an unspecified agent, classified in class 435, subclass 4.

VII. Claims 27-37, drawn to a second method of use of a polynucleotide encoding a granzyme B in inducing apoptosis in cells by introducing the polynucleotide into the cells, classified in class 514, subclass 44.

VIII. Claims 38 and 39 draw in part to, and claim 40 drawn entirely to, a method of detecting cells in an apoptotic or pre-apoptotic state by assessing cellular expression of a granzyme B-encoding mRNA transcript, classified in class 435, subclass 6.

IX. Claims 38 and 39 draw in part to, and claim 41 drawn entirely to, a method of detecting cells in an apoptotic or pre-apoptotic state by assessing cellular expression a granzyme B by detecting its presence, classified in class 435, subclass 7.4.

X. Claims 43-45, drawn to a method of modulating endogenous granzyme B expression by regulating the expression of a tumor suppression gene which, absent any designation of an agent, is classified in class 514, subclass 1.

XI. Claim 46, drawn to a method of modulating intracellular translocation of endogenous granzyme B by administering an adenovirus, classified in class 435, subclass 456.

XII. Claims 11, 12, and 47-50, drawn to a composition comprising, and to a gene therapy agent comprising, an expression construct and a nucleic acid sequence encoding the granzyme B amino acid sequence set forth in SEQ ID NO:3 - including SEQ IDs NOs:1 and 2 - and a method of treating a cancer by administering the expression construct to a patient, classified in class 435, subclass 320.1.

XIII. Claims 51-54 and 59, drawn to a method of inhibiting granzyme B by contacting tissues or cells with a composition comprising the inhibitor SPI-6, classified in class 514, subclass 2.

XIV. Claims 55-58 and 60, drawn to a method of inhibiting granzyme G by contacting tissues or cells with a composition comprising the inhibitor P1-9, classified in class 514, subclass 2.

XV. Claims 61-66, drawn to a method of using a cell comprising a polynucleotide encoding the granzyme B amino acid sequence set forth in SEQ ID NO:3 - including SEQ IDs NOs:1 and 2 - to identify a modulator of granzyme B expression, classified in class 435, subclass 252.3.

XVI. Claims 67-70, a method of inhibiting a granzyme B with a modulator that inhibits expression of granzyme B which, absent any designation of a modulator, is classified in class 435, subclass 23.

XVII. Claims 71-73, a method of inhibiting apoptosis in a cultured stem cell by introducing a modulator capable of inhibiting granzyme B expression, classified in class 435, subclass 455.

XVIII. Claims 74 and 75, drawn to progeny cells arising from less differentiated cells culture in the presence of a modulator capable of inhibiting granzyme B expression, classified in class 435, subclass 325.

In response, Applicant elects Group I, claims 1-10. Therefore, Applicant has canceled claims 11-75 drawn to non-elected inventions. If the Examiner has any questions or suggestions that would expedite examination of the elected claims, he is requested to please call the undersigned representative.

Respectfully submitted,



Stephen M. Hash
Reg. No. 45,490
Attorney for Applicant

VINSON & ELKINS L.L.P.
2300 First City Tower
1001 Fannin Street
Houston, Texas 77002-6760
512/542-8504

Date: December 8, 2004